EGFR-IN-169
Product Specifications
Target
ROS, Bcl-2 Family, Apoptosis, EGFR, CDK
Related Pathways
Apoptosis, Cell Cycle/Checkpoint, Angiogenesis, Tyrosine Kinase/Adaptors, JAK/STAT signaling, Immunology/Inflammation
Bioactivity
EGFR-IN-169 is an epidermal growth factor receptor (EGFR) inhibitor derived from ginsenoside, with an IC50 of 5.19 μM. It disrupts colorectal cancer cell migration and growth by inhibiting the EGFR-mediated RalA/EMT pathway. With an IC50 of 4.46 μM against HCT-116 cells and a selectivity index (SI) of 16.92, EGFR-IN-169 also inhibits CDKs, induces G0/G1 cell cycle arrest, and suppresses cell migration and invasion. Additionally, EGFR-IN-169 reduces mitochondrial membrane potential, induces apoptosis and reactive oxygen species (ROS) production. It is applicable in cancer research, particularly for colorectal cancer.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNCB2346-500 1x 500 µL
AIF1 / Iba1 (Microglia Marker) (rAIF1/1909), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 